What is it about?
Expression of the cancer/germ‐line antigen NY‐ESO‐1 by tumors elicits spontaneous humoral and cellular immune responses in some cancer patients.
Featured Image
Why is it important?
Single injection of rLV/ESO into HLA-A2-transgenic mice elicited long-lasting B and T cell responses against NY-ESO-1. CD8+ T cells against the HLA-A2-restricted peptide NY-ESO-1(157-165) were readily detectable ex vivo and showed restricted TCR Vbeta usage. Moreover, rLV/ESO elicited a far greater anti-NY-ESO-1(157-165) CD8+ T cell response than peptide- or protein-based vaccines. Anti-NY-ESO-1 antibodies were rapidly induced after immunization and their detection preceded that of the antigen-specific CD8+ T cells.
Read the Original
This page is a summary of: Lentivector immunization induces tumor antigen‐specific B and T cell responsesin vivo, European Journal of Immunology, July 2008, Wiley,
DOI: 10.1002/eji.200737923.
You can read the full text:
Resources
Contributors
The following have contributed to this page
